Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

By S. Yusuf, S. Mehta, S. Chrolavicius, Rizwan Afzal, Janice Pogue, C. Granger, A. Budaj, R. Peters, J. Bassand, L. Wallentin and 2 more. New England Journal of Medicine, 2006

1,144 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/2de9517974ac27804ffa15f6026f6df27949a83a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Hani Jneid
2. Allan S. Jaffe

Citations in the corpus

• Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. (2009, result): “Recent trials with agents that reduce the risk of bleeding with similar efficacy to standard therapy have shown reductions in mortality in acute coronary syndromes.(5) These data suggest a causative link between major bleeding and death and recurrent ischemic events.”
• Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans (2009, background): “…from fondaparinux, an indirect factor Xa inhibitor (Walenga et al., 1988; Samama and Gerotziafas, 2003; Simoons et al., 2004; Wong et al., 2006; Yusuf et al., 2006a,b; Schumacher et al., 2007) [prescribing information for Arixtra (fondaparinux sodium) injection,…”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.”